1. Home
  2. INMD vs SPTX Comparison

INMD vs SPTX Comparison

Compare INMD & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InMode Ltd.

INMD

InMode Ltd.

N/A

Current Price

$13.63

Market Cap

805.0M

Sector

Health Care

ML Signal

N/A

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$22.26

Market Cap

929.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INMD
SPTX
Founded
2008
2024
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
805.0M
929.8M
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
INMD
SPTX
Price
$13.63
$22.26
Analyst Decision
Hold
Strong Buy
Analyst Count
5
9
Target Price
$16.17
★ $37.13
AVG Volume (30 Days)
★ 524.4K
224.7K
Earning Date
11-11-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.30
N/A
P/E Ratio
$10.11
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$15.79
52 Week High
$16.67
$28.38

Technical Indicators

Market Signals
Indicator
INMD
SPTX
Relative Strength Index (RSI) 43.31 61.03
Support Level $13.27 $18.79
Resistance Level $13.98 $22.53
Average True Range (ATR) 0.37 1.50
MACD -0.01 0.31
Stochastic Oscillator 29.29 89.75

Price Performance

Historical Comparison
INMD
SPTX

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: